Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Treasury Shares (2016 - 2025)

Standard Biotools (LAB) has disclosed Treasury Shares for 4 consecutive years, with $46.5 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares changed 0.0% to $46.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.5 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $46.5 million for FY2025, 0.0% changed from the prior year.
  • Treasury Shares for Q4 2025 was $18.6 million at Standard Biotools, roughly flat from $18.6 million in the prior quarter.
  • The five-year high for Treasury Shares was $18.6 million in Q3 2025, with the low at -$18.6 million in Q2 2024.
  • Average Treasury Shares over 5 years is $519506.3, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Treasury Shares soared 961.63% in 2023, then changed 0.0% in 2025.
  • Over 4 years, Treasury Shares stood at $563000.0 in 2022, then skyrocketed by 961.63% to $6.0 million in 2023, then soared by 677.43% to $46.5 million in 2024, then changed by 0.0% to $46.5 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $46.5 million, $46.5 million, and $46.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.